November 11: The Week in Cancer News
California passes ballot initiative banning flavored tobacco products, and the FDA approves combination treatments for lung cancer.
Progress Against Cancer
California passes ballot initiative banning flavored tobacco products, and the FDA approves combination treatments for lung cancer.
A targeted therapy was approved for a subset of treatment-resistant ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment...
The FDA approved the immune checkpoint inhibitor tremelimumab to treat certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved the immunotherapeutic tremelimumab (Imjudo) in combination with the...
The CD30-targeted antibody-drug conjugate was approved for some children with blood cancer. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with certain cancer therapies for pediatric patients over...
Experts weigh in on a recent study appearing to show that colonoscopy had lower-than-expected efficacy for preventing colorectal cancer.
The immune checkpoint inhibitor cemiplimab-rwlc was approved in combination with chemotherapy for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) in combination with platinum-based...
Female patients less likely than men to be told about sexual side effects of treatment, and more from this week in cancer news.
Research has linked highly processed foods like deli meat to a higher risk of colorectal cancer in men.
Clinical trial finds select breast cancer patients can forgo surgery, and more from the week in cancer news.
The FDA granted accelerated approval to a targeted immunotherapy for patients with relapsed or refractory multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to teclistamab-cqyv (Tecvayli), a type of...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More